You are here
Calithera Biosciences to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference and the Leerink Partners Rare Disease & Oncology Roundtable
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced its participation at two upcoming healthcare investor conferences in October.
- Cantor Fitzgerald Global Healthcare Conference. On Tuesday, October 2, 2018, Susan M. Molineaux, Ph.D., the company’s Founder, President and Chief Executive Officer will present a corporate update at 9:10 a.m. EDT at the Cantor Fitzgerald Global Healthcare Conference in New York City.
- Leerink Partners Rare Disease & Oncology Roundtable. On Wednesday, October 3, 2018, Susan M. Molineaux, Ph.D., the company’s Founder, President and Chief Executive Officer will participate in a fireside chat to discuss immuno-oncology at the Leerink Partners Rare Disease & Oncology Roundtable being held in New York City at 8:30 a.m. EDT.
The presentations will be webcast live, and available for replay for up to 30 days at www.calithera.com in the Investor Relations section.
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera’s product candidate, CB-839, is a potent, selective, reversible and orally bioavailable inhibitor of glutaminase. CB-839 takes advantage of the pronounced dependency many cancers have on the nutrient glutamine for growth and survival. It is currently being evaluated in randomized clinical trials in combination with standard of care agents. INCB-001158 is an immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell suppression by myeloid-derived suppressor cells. Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the body’s cancer-fighting immune cells, known as cytotoxic T-cells. CB-1158 is being developed in collaboration with Incyte Corporation. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the timing of Calithera’s clinical trials, the clinical and commercial potential of its product candidates, Calithera’s ability to fund its clinical programs, and Calithera’s receipt of clinical data from its clinical trials. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The potential product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's periodic filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.
SOURCE: Calithera Biosciences, Inc.